# Topotecan

## Hycamtin inj 4mg

| 藥物代碼 | IHYC |
| :--- | :--- |
| 適應症 | Metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy. Small cell lung cancer sensitive disease after failure of 1st-line chemotherapy. |
| 副作用 | Neutropenia, leucopenia, thrombocytopenia, anemia, sepsis. GI disturbances, fatigue, fever, pain, asthenia, alopecia, rash, coughing, dyspnea, headacheDermatologic: Alopecia \(IV, 49% ; oral, 10% to 20% \), Rash \(IV, 16% \)Gastrointestinal: Abdominal pain \(5% to 22% \), Constipation \(5% to 29% \), Diarrhea \(IV, 6% to 32% ; oral, 14% to 22% \), Nausea \(IV, 8% to 64% ; oral, 27% to 33% \), Stomatitis \(6% to 18% \), Vomiting \(IV, 10% to 45% ; oral, 19% to 21% \)Hematologic: Anemia \(IV, 89% to 94% ; oral, 94% to 98% \), Leukopenia \(IV, 91% to 97% ; oral, 86% to 90% \), Neutropenia \(IV, 89% to 97% ; oral, 83% to 91% \), Thrombocytopenia \(IV, 69% to 74% ; oral, 81% \)Neurologic: Asthenia \(IV, 25% ; oral, 3% to 7% \), Headache \(IV, 18% \), Pain \(23% \)Respiratory: Cough \(15% \), Dyspnea \(6% to 22% \)Other: Fatigue \(IV, 29% ; oral, 11% to 19% \), Fever \(28%, intravenous ; 5% to 7%, oral \) |
| 禁忌 | Severe hypersensitivity to topotecan or any component of the formulation. Canadian labeling: Additional contraindications \(not in the US labeling\): Severe renal impairment \(CrCl &lt;20 mL/minute\); pregnancy; breastfeeding; severe bone marrow depression |
| 懷孕用藥危分級 | 儘量避免 |
| 孕期用藥建議 | N/A |
| 附帶說明 | N/A |
| 哺乳期用藥建議 | No \(Limited\) Human Data - Potential Toxicity\(Mother\) 無\(很少\)資料 - 避免使用\(母體\) |
| 附帶說明 | N/A |
| 注射劑給藥建議途徑 | IVD |
| 乾粉稀釋液 | N/A |
| 輸注點滴液 | N/A |
| IVP 用法建議 | N/A |
| IVD 用法建議 | N/A |
| 注意事項 | 1. Topotecan 4 mg 粉末須以4 mL D/W泡製，泡製後之溶液濃度 1mg/mL。泡製後溶液需以適當體積N/S或D5W進一步稀釋，最終濃度 25 - 50 mcg/mL。 2. 監測CBC、肝腎功能，注意是否出現間質性肺病症狀 \(咳嗽、發燒、呼吸困難或缺氧\)。 |

